SCHEMBL12373938

SCHEMBL12373938

CC(C)Oc1ccc(-c2nn(C)c3ccc([N+](=O)[O-])cc23)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
CNR2 P34972 5/20 0.44
SCN9A Q15858 3/20 0.41
ACHE P22303 2/20 0.39
CNR1 P21554 1/20 0.39
SCN5A Q14524 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 3/20 0.38
PDE10A Q9Y233 1/20 0.38
FLT3 P36888 1/20 0.37
SYK P43405 1/20 0.37
PTPN11 Q06124 1/20 0.36
F2RL3 Q96RI0 1/20 0.35
ALDH1A1 P00352 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12374208 0.85 L3MBTL1 (0.60) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL12374159 0.83 L3MBTL1 (0.57) L3MBTL1CNR2SCN9AACHECNR1
SCHEMBL18113578 0.83 L3MBTL1 (0.47) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL12374158 0.82 L3MBTL1 (0.67) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL13854973 0.81 L3MBTL1 (0.66) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL12373945 0.81 PIK3CA (0.42) L3MBTL1SCN9ASCN5APDE10AFLT3
SCHEMBL13854980 0.76 L3MBTL1 (0.68) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL13855022 0.75 L3MBTL1 (0.67) L3MBTL1CNR2ACHECNR1MEN1
SCHEMBL12374192 0.75 L3MBTL1 (0.63) L3MBTL1CNR2ACHECNR1MAPT
SCHEMBL20379350 0.73 L3MBTL1 (0.68) L3MBTL1CNR2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180000803-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS MERCK SHARP & DOHME CORP. (US) 2018-01-04 US disclosed
US-20170362202-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS MERCK SHARP & DOHME CORP. (US) 2017-12-21 US disclosed
US-8716483-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-05-06 US disclosed
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362202-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HINT1 L3MBTL1 4674/4885CNR2 1155/4885SCN9A 1723/4885
US-20180000803-A1 (S)-N-(3-(6-ISOPROPOXYPYRIDIN-3-YL)-1H-INDAZOL-5-YL)-1-(2-(4-(4-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)-2-OXOETHYL)-3-(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS S100P, TSLP, TPSAB1 L3MBTL1 4771/4885CNR2 1948/4885SCN9A 365/4885
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 L3MBTL1 3012/4885CNR2 3669/4885SCN9A 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.